Navigation Links
Fujirebio announces coverage by Cigna for ROMA® (Risk of Ovarian Malignancy Algorithm)
Date:5/21/2020

Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings, Inc. and an industry leader in cancer biomarker assays, announced today that Cigna has added ROMA® (Risk of Ovarian Malignancy Algorithm) to its national preferred coverage list. Cigna Corporation is a global health service company dedicated to improving the health, well-being, and peace of mind of the customers they serve. This decision to add ROMA further demonstrates Cigna’s focus to help reduce patient health costs and achieve optimal health outcomes.

The ACOG (American College of Obstetricians and Gynecologists) recommendations include ROMA as one of several risk assessment algorithms when referring patients with an adnexal mass. ROMA is a qualitative test that combines the quantitative results of HE4, CA 125 and menopausal status into a numerical score. It can be performed in any laboratory that also provides CA 125 testing services. Each ROMA result automatically includes the individual results of CA 125, HE4 and the ROMA score. ROMA is intended to aid in assessing whether premenopausal or postmenopausal women who present with an ovarian adnexal mass are at high or low likelihood of finding malignancy on surgery. CA 125 is within normal limits in 50% of women with stage 1 disease, is often falsely positive in benign conditions like endometriosis, and is not approved as a risk assessment tool for ovarian masses. ROMA helps to address some of these shortcomings.

“With over 21,000 women in the U.S. diagnosed per year with ovarian cancer, we are pleased to see the increase in the number of women who will now have access to ROMA,” says Monte Wiltse, CEO/President at Fujirebio Diagnostics, Inc. “Early and appropriate care by a gynecologic oncologist can help increase survival rates in women with ovarian cancer and decrease the number of complications.”

About Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pioneered and introduced CA 125, the first FDA approved ovarian cancer biomarker, over 25 years ago and introduced HE4 and ROMA for ovarian cancer management in 2008 and 2011, respectively. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in vitro diagnostic products for the management of human disease states, with an emphasis in oncology. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at http://www.he4test.com.

About Fujirebio

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

Fujirebio is a wholly-owned subsidiary of Miraca Holdings Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

Read the full story at https://www.prweb.com/releases/fujirebio_announces_coverage_by_cigna_for_roma_risk_of_ovarian_malignancy_algorithm/prweb17141375.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine news :

1. Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G whole PTH Assay
2. Diet Doc’s Prescription Hormone Diets & Weight Loss Plans Announces New Clean Eating Diet Plans to Slim the Waistline While Reducing the Risk for Colorectal Cancer
3. EmpowHER’s Michelle King Robson Announces Launch of HER Radio – Exploring all things Woman
4. Innovations with Ed Begley, Jr. Announces New Episode Airing November 14, 2013 via Discovery Channel
5. T.E.N. Announces Winners of the ISE® North America Awards
6. AED.com Announces That All Employees Now Carry a Personal AED
7. Phoenix Treatment Center Announces New Video Explaining Its Services for Drug, Alcohol Addiction
8. Innovaacom Announces November Launch of New Hospital-Based Physician Training Program
9. Coffee Beanery Announces Grand Opening of New Store in Memorial City Mall
10. Wichita Drug Rehab Announces New Video Explaining Services Offered Through Drug Addiction Treatment Centers
11. PriceAngels.com Announces Its Cheapest Android Tablet Collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2020)... ... May 28, 2020 , ... ... joining the clinically integrated network (CIN) and the group purchasing organization run by ... Institute to establish a heart failure program at Mon Health Medical Center. ...
(Date:5/28/2020)... Ala. (PRWEB) , ... May 28, 2020 , ... ... plans to fully re-open in the fall, operators of student housing are scrambling ... they return. COCM, which manages over 37,000 student housing beds on 38 campuses ...
(Date:5/27/2020)... FOWLERVILLE, Mich. (PRWEB) , ... May 27, 2020 , ... ... the Covid-19 curve and Howell Michigan, Fowlerville Michigan , and Ann Arbor Michigan. ... by seeing all high-risk patients within the clinic and at the hospital. We have ...
(Date:5/27/2020)... PASS, Ore. (PRWEB) , ... ... ... 25 May 2020 , Guest: Dr. Gerald Pollack, University of Washington Professor ... Fourth Phase of Water: Beyond Solid, Liquid & Vapor ( https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2 ) ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... two leading RevSpring solutions—Talksoft® patient messaging and IVR Advantage™--for Loyale customers. Talksoft ... through automated and precise texts, IVR reminders and email messages tailored to ...
Breaking Medicine News(10 mins):
(Date:5/26/2020)... ... May 26, 2020 , ... ... dicentra , seeking to provide them with revolutionary clinical trial solutions. , ... management platform, an end-to-end solution that enables onboarding, scheduling, and remote data capture ...
(Date:5/21/2020)... ... May 21, 2020 , ... Latham Pool Products ... manufacture 25,000 polymer film gowns that will be worn by doctors and nurses ... pools and accessories, is excited to give back to the community in a ...
(Date:5/21/2020)... Ohio (PRWEB) , ... May 21, 2020 , ... ... pandemic, U.S. healthcare providers nationwide began implementing telehealth solutions in order to continue ... survey from Updox , the place for virtual care and complete healthcare ...
Breaking Medicine Technology: